Transasia launches Made In India ErbaLisa COVID-19 IgG ELISA test kit

Currently made at Daman facility, production to shift to AMTZ, Visakhapatnam, where at full capacity, six lakh tests will be manufactured per day

Transasia Bio-Medicals has launched Made in India ErbaLisa COVID-19 IgG ELISA-based antibody test kits for detection of COVID-19. Designed and developed in India, the ErbaLisa COVID-19 IgG ELISA kits have been validated for a proven sensitivity and specificity of >99 per cent and are suitable for use on all widely available semi and fully automated ELISA systems, as per a company release.

ErbaLisa COVID-19 IgG kit has been evaluated and approved by National AIDS Research Institute (NARI), Pune, and is included in the ICMR’s list of validated COVID-19 IgG antibody tests. The kits have also approved by CE IVD.

“For the last 40 years, Transasia has been meeting the needs for quality, diagnostic solutions that are accessible and affordable. Very early on, we identified that manufacturing in India is the only way forward to reduce the dependency on imports and make India truly ATMA NIRBHAR. Our ErbaLisa COVID-19 IgG ELISA kits are a result of dedicated efforts of our R&D team in India. We are proud to remain committed to ATMA NIRBHAR BHARAT by manufacturing these kits in India”, said Suresh Vazirani, CMD, Transasia-Erba group.

“We are thankful to ICMR and NARI for acknowledging our efforts in developing the COVID-19 testing kits. This approval has come at the right time, as India ramps up its testing capacity and inches towards normalcy. Manufacturing these kits in India will help us further offer affordable kits that are accessible to the citizens of India and contribute to the government’s strategy of test, treat and track,” added Ravi Kaushik, CEO, Transasia Bio-Medicals.

The kit offers the following advantages:

• Sample required for test – Blood Serum/Plasma
• Assay time – 90 min
• Simplified protocol with In-Well Sample Dilution
• Ready to use reagents
• Semi-quantitative result
• > 99 per cent sensitivity and specificity
• Adaptable to automation

The ready-to-use ErbaLisa COVID-19 IgG ELISA kits can reportedly test up to 96 samples and give results in a couple of hours.  They are being therefore positioned as an effective tool for surveillance and epidemiological study to identify the high risk or vulnerable populations like healthcare workers, factory workers, immune-compromised patients and individuals in containment zones as well as asymptomatic individuals and those who would have already recovered.

“The government has put in a lot of efforts to slow down the surge in the spread of the infection in India. As a company that is truly Indian by heart, we are proud to contribute to the fight against COVID-19. This kit is made in India for the people of India and is dedicated to all COVID heroes who have been relentlessly, ensuring the health of the nation, often putting their own health at risk,” concluded Anil Jotwani, Sr. President, Sales & Marketing, Transasia Bio-Medicals.

In line with Prime Minister Narendra Modi’s vision of ATMA NIRBHAR BHARAT, Transasia has initiated the manufacturing of these kits at its existing facility in Daman. Further, it will soon start rolling out the kits from its ultra-modern manufacturing facility at AMTZ, Visakhapatnam. Sprawling over 35,000 square feet, this plant is backed by the World Health Organization (WHO). In its full capacity, six lakh tests will be manufactured per day.